Colorectal cancer (CRC) remains a leading causes of cancer-related death in the world, mainly due to the lack of effective treatment of advanced disease. TNF-related apoptosis-inducing ligand (TRAIL)-driven cell death, a crucial event in the control of tumor growth, selectively targets malignant rather than non-transformed cells. However, the fact that cancer cells, including CRC cells, are either intrinsically resistant or acquire resistance to TRAIL, represents a major hurdle to the use of TRAIL-based strategies in the clinic. Agents able to overcome CRC cell resistance to TRAIL have thus great therapeutic potential and many researchers are making efforts to identify TRAIL sensitizers. The anthelmintic drug rafoxanide has recently emerged as a potent anti-tumor molecule for different cancer types and we recently reported that rafoxanide restrained the proliferation of CRC cells, but not of normal colonic epithelial cells, both in vitro and in a preclinical model mimicking sporadic CRC. As these findings were linked with the induction of endoplasmic reticulum stress, a phenomenon involved in the regu-lation of various components of the TRAIL-driven apoptotic pathway, we sought to determine whether rafox-anide could restore the sensitivity of CRC cells to TRAIL. Our data show that rafoxanide acts as a selective TRAIL sensitizer in vitro and in a syngeneic experimental model of CRC, by decreasing the levels of c-FLIP and survivin, two key molecules conferring TRAIL resistance. Collectively, our data suggest that rafoxanide could potentially be deployed as an anti-cancer drug in the combinatorial approaches aimed at overcoming CRC cell resistance to TRAIL-based therapies.

Laudisi, F., Pacifico, T., Maresca, C., Luiz-Ferreira, A., Antonelli, S., Ortenzi, A., et al. (2022). Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis. BIOMÉDECINE & PHARMACOTHÉRAPIE, 155, 1-11 [10.1016/j.biopha.2022.113794].

Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis

Ortenzi, Angela;Colantoni, Alfredo;Monteleone, Ivan;Monteleone, Giovanni;Stolfi, Carmine
2022-11-01

Abstract

Colorectal cancer (CRC) remains a leading causes of cancer-related death in the world, mainly due to the lack of effective treatment of advanced disease. TNF-related apoptosis-inducing ligand (TRAIL)-driven cell death, a crucial event in the control of tumor growth, selectively targets malignant rather than non-transformed cells. However, the fact that cancer cells, including CRC cells, are either intrinsically resistant or acquire resistance to TRAIL, represents a major hurdle to the use of TRAIL-based strategies in the clinic. Agents able to overcome CRC cell resistance to TRAIL have thus great therapeutic potential and many researchers are making efforts to identify TRAIL sensitizers. The anthelmintic drug rafoxanide has recently emerged as a potent anti-tumor molecule for different cancer types and we recently reported that rafoxanide restrained the proliferation of CRC cells, but not of normal colonic epithelial cells, both in vitro and in a preclinical model mimicking sporadic CRC. As these findings were linked with the induction of endoplasmic reticulum stress, a phenomenon involved in the regu-lation of various components of the TRAIL-driven apoptotic pathway, we sought to determine whether rafox-anide could restore the sensitivity of CRC cells to TRAIL. Our data show that rafoxanide acts as a selective TRAIL sensitizer in vitro and in a syngeneic experimental model of CRC, by decreasing the levels of c-FLIP and survivin, two key molecules conferring TRAIL resistance. Collectively, our data suggest that rafoxanide could potentially be deployed as an anti-cancer drug in the combinatorial approaches aimed at overcoming CRC cell resistance to TRAIL-based therapies.
nov-2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
English
C-FLIP
DR5
Drug repurposing
Endoplasmic reticulum stress
Survivin
Laudisi, F., Pacifico, T., Maresca, C., Luiz-Ferreira, A., Antonelli, S., Ortenzi, A., et al. (2022). Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis. BIOMÉDECINE & PHARMACOTHÉRAPIE, 155, 1-11 [10.1016/j.biopha.2022.113794].
Laudisi, F; Pacifico, T; Maresca, C; Luiz-Ferreira, A; Antonelli, S; Ortenzi, A; Colantoni, A; Di Grazia, A; Franzè, E; Colella, M; Di Fusco, D; Sica, Gs; Monteleone, I; Monteleone, G; Stolfi, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2022-Biomed & pharm RFX and TRAIL.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 6.29 MB
Formato Adobe PDF
6.29 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/311721
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact